Status:
NOT_YET_RECRUITING
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Lead Sponsor:
ARCE Therapeutics, Inc.
Conditions:
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia, in Relapsed or Refractory
Eligibility:
All Genders
Brief Summary
This study will evaluate the long-term safety of ARD103 cellular therapies
Detailed Description
Participants who receive administration of ARD103 (i.e., a partial dose or a full dose) will roll into the LTFU study upon completion of the 24-month interventional study period (Study: ARD103\_ARCE-C...
Eligibility Criteria
Inclusion
- The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
- The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.
Exclusion
- There are no specific exclusion criteria for this study
Key Trial Info
Start Date :
March 15 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2040
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT06906380
Start Date
March 15 2026
End Date
October 31 2040
Last Update
December 8 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Novant Health Cancer Institute
Charlotte, North Carolina, United States, 28204
2
Novant Health Cancer Institute
Winston-Salem, North Carolina, United States, 27201
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030